Med. praxi. 2017;14(2):37-45

Neuropsychiatric disorders in multiple sclerosis

MUDr. Petra Nytrová1, 2, Mgr. Jana Blahová Dušánková1, MUDr. Alexander Nawka2
1Neurologická klinika a Centrum klinických neurověd, Univerzita Karlova v Praze, 1. lékařská fakulta a Všeobecná fakultní nemocnice v Praze
2Institut neuropsychiatrické péče Praha

Multiple sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system with a relatively high variability of symptoms

based on the site of inflammatory lesions in the brain and spinal cord. The diagnosis of MS has a profound psychological and

social impact on the individual. Accepting the diagnosis is impaired by, to a certain extent, unpredictable disease course or treatment

complications. The lifetime prevalence of affective and anxiety disorders is higher in these patients than in the general population. The

patient’s condition may further be complicated by cognitive impairment of varying degrees. Early diagnosis and appropriate treatment of

neuropsychiatric disorders in MS patients have crucial significance not only for improving the quality of life, but also the basic treatment.

Keywords: multiple sclerosis, affective disorders, cognitive impairment

Published: May 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nytrová P, Blahová Dušánková J, Nawka A. Neuropsychiatric disorders in multiple sclerosis. Med. praxi. 2017;14(2):37-45.
Download citation

References

  1. Amato MP, Langdon D, Montalban X, Benedict RH, DeLuca J, Krupp LB, Thompson AJ, Comi G. Treatment of cognitive impairment in multiple sclerosis: position paper. Journal of neurology 2013; 260: 1452-1468. Go to original source... Go to PubMed...
  2. Amato MP, Portaccio E, Goretti B, Zipoli V, Hakiki B, Giannini M, Pasto L, Razzolini L. Cognitive impairment in early stages of multiple sclerosis. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2010; 31: S211-214. Go to original source... Go to PubMed...
  3. Andreasen AK, Spliid PE, Andersen H, Jakobsen J. Fatigue and processing speed are related in multiple sclerosis. European journal of neurology : the official journal of the European Federation of Neurological Societies 2010; 17: 212-218. Go to original source... Go to PubMed...
  4. Barak Y, Achiron A. Effect of interferon-beta-1b on cognitive functions in multiple sclerosis. European neurology 2002; 47: 11-14. Go to original source... Go to PubMed...
  5. Benedict RH, Morrow SA, Weinstock Guttman B, Cookfair D, Schretlen DJ. Cognitive reserve moderates decline in information processing speed in multiple sclerosis patients. Journal of the International Neuropsychological Society : JINS 2010; 16: 829-835. Go to original source... Go to PubMed...
  6. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nature reviews Neurology 2011; 7: 332-342. Go to original source... Go to PubMed...
  7. Bermel RA, Hashmonay R, Meng X, Randhawa S, von Rosenstiel P, Sfikas N, Kantor D. Fingolimod first-dose effects in patients with relapsing multiple sclerosis concomitantly receiving selective serotonin-reuptake inhibitors. Multiple sclerosis and related disorders 2015; 4: 273-280. Go to original source... Go to PubMed...
  8. Calabrese M, Agosta F, Rinaldi F, Mattisi I, Grossi P, Favaretto A, Atzori M, Bernardi V, Barachino L, Rinaldi L, Perini P, Gallo P, Filippi M. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Archives of neurology 2009; 66: 1144-1150. Go to original source... Go to PubMed...
  9. Dusankova JB, Kalincik T, Havrdova E, Benedict RH. Cross cultural validation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) and the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). The Clinical neuropsychologist 2012; 26: 1186-1200. Go to original source... Go to PubMed...
  10. Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. Journal of the neurological sciences 2006; 245: 63-66. Go to original source... Go to PubMed...
  11. Feinstein A. Multiple sclerosis and depression. Multiple sclerosis 2011; 17: 1276-1281. Go to original source... Go to PubMed...
  12. Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Annals of neurology 2000; 48: 885-892. Go to original source...
  13. Galeazzi GM, Ferrari S, Giaroli G, Mackinnon A, Merelli E, Motti L, Rigatelli M. Psychiatric disorders and depression in multiple sclerosis outpatients: impact of disability and interferon beta therapy. Neurological sciences: official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2005; 26: 255-262. Go to original source... Go to PubMed...
  14. Ghaffar O, Feinstein A. The neuropsychiatry of multiple sclerosis: a review of recent developments. Current opinion in psychiatry 2007; 20: 278-285. Go to original source... Go to PubMed...
  15. Grassiot B, Desgranges B, Eustache F, Defer G. Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review. Journal of neurology 2009; 256: 1397-1412. Go to original source... Go to PubMed...
  16. Hanna J, Feinstein A, Morrow SA. The association of pathological laughing and crying and cognitive impairment in multiple sclerosis. Journal of the neurological sciences 2016; 361: 200-203. Go to original source... Go to PubMed...
  17. Hunter SF, Agius M, Miller DM, Cutter G, Barbato L, McCague K, Meng X, Agashivala N, Chin P, Hollander E. Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial. Journal of the neurological sciences 2016; 365: 190-198. Go to original source... Go to PubMed...
  18. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. The Lancet Neurology 2008; 7: 1139-1151. Go to original source... Go to PubMed...
  19. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller DH, Montalban X, Barkhof F, Radu EW, Metzig C, Bauer L, Lanius V, Sandbrink R, Pohl C, Group BS. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. The Lancet Neurology 2009; 8: 987-997. Go to original source... Go to PubMed...
  20. Korostil M, Feinstein A. Anxiety disorders and their clinical correlates in multiple sclerosis patients. Multiple sclerosis 2007; 13: 67-72. Go to original source... Go to PubMed...
  21. Krupp LB, Christodoulou C, Melville P, Scherl WF, Pai LY, Muenz LR, He D, Benedict RH, Goodman A, Rizvi S, Schwid SR, Weinstock-Guttman B, Westervelt HJ, Wishart H. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology 2011 76: 1500-1507. Go to original source... Go to PubMed...
  22. Langdon DW. Cognition in multiple sclerosis. Current opinion in neurology 2011; 24: 244-249. Go to original source... Go to PubMed...
  23. Langdon DW, Amato MP, Boringa J, Brochet B, Foley F, Fredrikson S, Hamalainen P, Hartung HP, Krupp L, Penner IK, Reder AT, Benedict RH. Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS). Multiple sclerosis 2012; 18: 891-898. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.